X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Health & Nutrition

Bio-Gate and Avicanna complete first phase of development on CBD and Micro Silver BG based skin care products for global commercialization

Content Team by Content Team
30th June 2021
in Health & Nutrition, Press Statements
Bio-Gate and Avicanna complete first phase of development on CBD and Micro Silver BG based skin care products for global commercialization

Bio-Gate AG, a leading provider of innovative technologies and individual solutions for health and hygiene, has completed the initial development phase for prospective products through a licensing and development agreement with Avicanna Inc., a Canadian bio-pharmaceutical company, to enter the rapidly growing cannabidiol (CBD) market.

As part of the collaboration, Bio-Gate is developing active cosmetic and dermatology products in collaboration with Avicanna that combine MicroSilver BG™ and CBD (hemp derived) to deliver synergistic anti-inflammatory and antimicrobial effects. Following the development and initial success of in vitro studies, the products will be available for human applications shortly. Target indications and cosmetic benefits of the products include acne, eczema andatopic dermatitis.  The products will be initially marketed in Europe and North America.  The newly developed products comply with current EU regulations under cosmetic designation and will be made available to existing clients of Bio-Gate in Europe and North America who have expressed significant interest.

Avicanna has extensive experience with cannabinoid product development and has commercialized CBD based skin care products across several markets including North and South America where they will lead commercial efforts on the newly developed products as well. Bio-Gate is primarily responsible for sales and commercialization in European markets. The cooperation with Avicanna follows Bio-Gate’s strategy of gradually transferring technologies to new business and application areas, thus opening new markets with new product applications.

Marc Lloret-Grau, CEO of Bio-Gate AG, on the new cooperation: “We are delighted to have Avicanna as our strategic partner as a leading cannabinoid biopharmaceutical company that focuses on cosmetics, skincare and medical based product applications. The collaboration represents a bridge for Bio-Gate to further new technologies. We are once again expanding our product range and thus tapping into a new and extremely high-growth market.”

Aras Azadian, CEO of Avicanna Inc stated “ We thrilled to announce our partnership and achievement of our initial milestones with Bio-Gate, a European bio-medical company with focus on health technologies like dermatology and skin care as well. We are also optimistic about the potential combination of Avicanna’s intellectual property with that of Bio-Gate’s in addition to the market access and expertise that the two companies can provide in this collaboration.

About Bio-Gate:

Bio-Gate AG is one of the world’s leading providers of innovative technologies and customised solutions for health and hygiene. Our aim is to make living together safer and healthier and to improve the well-being of all individuals. Bio-Gate enhances materials and products with its technologies and antimicrobial and antiviral strategies, and, thereby improves the quality of life of people and animals alike. The company specializes in equipping materials and surfaces with antiviral and antimicrobial properties. Bio-Gate AG enhances materials and products, particularly in the field of medical technology, such as the coating of implants or wound dressings. In addition, Bio-Gate technologies are used to provide consumer, industrial and hygiene products, such as paints, coatings, plastics or protective film sprays with antiviral and antimicrobial properties, thus enhancing them in a unique way. Bio-Gate also uses its unique and multi-functional additive MicroSilver BG in dermatology and cosmetics as well as wound care to provide these kind of products with long-lasting antimicrobial, anti-inflammatory and Microbiome friendly properties.

Previous Post

Drug delivery innovation across Europe improves for third consecutive year ahead of Pharmapack Europe

Next Post

BioMed X and Merck KGaA, Darmstadt, Germany launch new research program in oncology

Related Posts

Envirotainer introduces the RAP for the future - part of the Releye series
Packaging & Logistic

Envirotainer introduces the RAP for the future – part of the Releye series

14th February 2022
United Cargo Meets Growing Demand for Pharmaceuticals with New TempControl Containers
Packaging & Logistic

Opticooler receives technical approval by Japanese major airlines

14th February 2022
Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease
Press Statements

Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease

14th February 2022
Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials
Clinical Trials

Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

7th February 2022
Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations
Press Statements

New Zealand’s Medsafe Grants Provisional Approval for Novavax COVID-19 Vaccine

7th February 2022
First own Gerresheimer Autoinjector - Gerresheimer and Midas Pharma announce strategic partnership
Packaging & Logistic

The leading supplier of injection vials Gerresheimer expands production in Wertheim

7th February 2022
Next Post
FDA Approves Eli Lilly Precision Oncology Treatment for Certain Lung and Thyroid Cancers

BioMed X and Merck KGaA, Darmstadt, Germany launch new research program in oncology

Latest News

Envirotainer introduces the RAP for the future - part of the Releye series
Packaging & Logistic

Envirotainer introduces the RAP for the future – part of the Releye series

14th February 2022
United Cargo Meets Growing Demand for Pharmaceuticals with New TempControl Containers
Packaging & Logistic

Opticooler receives technical approval by Japanese major airlines

14th February 2022
Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease
Press Statements

Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease

14th February 2022
Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
News

Indian Scientists Claim To Design Vaccine For All Variants

9th February 2022
Drones for Delivery To Carry Pharmaceutical Weight Forward
News

Drones for Delivery To Carry Pharmaceutical Weight Forward

9th February 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In